US Device Biocompatibility Guidance Adds Nanotech, Absorbability Test Tips
This article was originally published in SRA
Executive Summary
A long-awaited final guidance from the US Food and Drug Administration covering biocompatibility testing of medical devices adds several new sections compared with a draft version issued in April 2013, including recommendations for taking a risk-based approach to biological testing of materials, chemical testing, and test-article preparation for devices with nanotech and submicron components1-3.
You may also be interested in...
New FDA Site Walks Sponsors Step-By-Step Through Biocompatibility Requirements
The agency has developed a user-friendly four-step process sponsors can use to address biocompatibility issues based on its 2016 biocompatibility guidance.
FDA Focusing More On Safety Of Device Biomaterials, Attorney Warns
Device-makers will have to take a more proactive approach to understanding the safety of biomaterials they use for their implanted devices, and how these materials might affect patients during post-market use, industry attorney Michele Buenafe of Morgan Lewis & Bockius LLP told Medtech Insight in a March 18 interview.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.